The data from a preclinical disease model in mice presented at ASH, shows that sevuparin could represent a major advance in the treatment of anemia in chronic kidney disease and other disorders with chronic inflammation. About 10% of the general population is assumed to have Chronic Kidney Disease (CKD) at stages 3-5 and in approximately ¼ of these, the condition is aggravated by anemia. In anemia, the number of red blood cells in the body or the hemoglobin concentration within them is lower than normal and when present in CKD, it significantly contributes to the overall disease. In addition to the effects on anemia, sevuparin also ameliorated kidney function and fibrosis in the treated animals.
The poster, entitled “The Heparinoid Sevuparin Improves Anemia and Kidney Status in a Mouse Model of Chronic Kidney Disease” were presented as a poster by Dr
The presentation included:
- Results describing the effects of sevuparin for up to 3 weeks on hemoglobin and other anemia measures as well as on kidney function and tissue fibrosis during experimental kidney disease in treated vs. untreated mice.
- Results describing the effects of sevuparin together with erythropoietin (EPO) for up to 6 weeks on hemoglobin and other anemia measures as well as on kidney function and tissue fibrosis during experimental kidney disease in treated vs. untreated mice and mice treated with EPO alone.
The abstract can be found here:
https://ash.confex.com/ash/2023/webprogram/Paper181587.html
John Öhd continues: “It is particularly encouraging that even as the effect of EPO alone was decreasing over time in the model, this could be counteracted by the addition of sevuparin along with stable maintenance of the effect on anemia. In the clinical setting, it is not uncommon for CKD patients to gradually become hyporesponsive to the standard of care, which opens of for potential uses of sevuparin in this setting.”
© Modular Finance, source